Lakewood-Amedex Biotherapeutics Inc.
corporate_fare Company Profile
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for LABT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LABT spans 8-K, S-1, 10-Q, DEF 14A.
Recent high-impact activity:
- Shareholders Approve 8x Authorized Share Increase and Reverse Split Authority
- First Patient Dosed in Phase 2a Trial of Nu-3 for Diabetic Foot Ulcers
- Lakewood-Amedex Registers 4.5M Additional Shares for Series C Holder Resale
- Lakewood-Amedex Reports Q2 Loss, Unremediated Material Weaknesses, and $1.17M Phase 2a Commitments
- Lakewood-Amedex Seeks Shareholder Nod for 8x Authorized Share Hike and Reverse Split Authority
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 52,967 shares in LABT as of the September 15, 2026 settlement, a 13.7% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 37.2% of LABT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for LABT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-17.
Massive Dilution Confirmed · Ongoing Going Concern Warning
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →